SAN LUIS OBISPO, Calif. – May. 15, 2003 – FzioMed, Inc. announces that positive clinical study results of Oxiplex/SP Gel were published in the May 2003 issue of Spine (Volume 28, pages 1080-1088). The peer-review article reports the reduction of pain and radiculopathy with the use of Oxiplex/SP Gel after laminectomy, laminotomy and discectomy surgery.
The objectives of the pilot clinical study were to evaluate safety and assess the efficacy of Oxiplex/SP Gel. The article concluded that Oxiplex/SP Gel was easy to use and safe for patients undergoing unilateral discectomy surgery and that greater clinical benefit was seen in patients treated with Oxiplex/SP Gel, especially those with severe leg pain and weakness at baseline. A pivotal clinical trial of Oxiplex/SP Gel is underway in the United States.
FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company’s patented Oxiplex platform technology. Oxiplex is an innovative polymer material that is formulated for a variety of surgical indications and markets. Products include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products are at various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.